Trials / Unknown
UnknownNCT04830644
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Iguratimod in Patients With Active Primary Sjogren's Syndrome.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iguratimod | Iguratimod orally twice a day |
| DRUG | Placebo | Placebo orally twice a day |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2022-04-01
- Completion
- 2022-06-01
- First posted
- 2021-04-05
- Last updated
- 2021-07-19
Locations
30 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04830644. Inclusion in this directory is not an endorsement.